Drug intelligence / Profile preview

cisplatin + docetaxel + icotinib

Development stage: Unknown
Lead developer: Betta Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination therapy consisting of two chemotherapy agents (cisplatin and docetaxel) and an EGFR tyrosine kinase inhibitor (icotinib). This combination is being studied for the treatment of non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations. Research suggests that the sequence of administration (chemotherapy followed by EGFR-TKI) may be important for optimal efficacy. Clinical studies have shown that icotinib alone may provide better disease-free survival and reduced toxicity compared to cisplatin plus docetaxel in certain NSCLC patients with EGFR mutations.

Targets

EGFR (Epidermal growth factor receptor)Microtubule

Beyond the preview

Go deeper on cisplatin + docetaxel + icotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on cisplatin + docetaxel + icotinib.

Explore the full profile